This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

3,4-DAP (Jacobus)

Jacobus Pharmaceutical Company

Drug Names(s): 3,4-diaminopyridine, amifampridine

Description: The active substance of amifampridine phosphate is a potassium channel blocker which increases the release of acetylcholine and helps the muscle to receive the nerve signals. 3,4-Diaminopyridine is an organic compound with the formula C5H3N(NH2)2. It is formally derived from pyridine by substitution of the 3 and 4 positions with an amino group.

3,4-DAP (Jacobus) News

Pink Sheet FDA Broke Catalyst's Orphan Exclusivity Due To Pricing, Not Clinical, Concerns, Firm Claims

Scrip Catalyst Will Try To Salvage Rare Disease Drug from Failed Phase III Trial

Pink Sheet Catalyst Alleges US FDA 'Facilitating' Off-Label Use With Jacobus' Ruzurgi Approval

Scrip Pipeline Watch: Phase III Starts For Linzagolix, RTB101

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug